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To the Editor:
Hughes et al. 1 suggested that a common deletion of the CFHR1 and CFHR3 genes (CFHR1-3∆) is associated with lower risk of age related macular degeneration (AMD) and that the effect is independent from that of the previously described Y402H allele (rs1061170) in the adjacent CFH gene 2 . Others have replicated the CFHR1-3∆ association 3, 4 , and this has spurred further research on the function of the CFHR gene family 5 . In addition to the Y402H coding variant, we and others have described a second independent CFH allele, marked by the rs1410996 intronic SNP 6, 7 .
Since the CFH-CFHR1-CFHR3 genomic region containing both of these risk SNPs and CFHR1-3∆ has strong linkage disequilibrium (see Supplementary Fig. 1 ) with common haplotypes extending across the entire region 4 , we sought to understand the relationship between these AMD associations in a large sample collection. This issue is potentially relevant to atypical hemolytic uremic syndrome (MIM235400), which has also been linked separately to CFH alleles and to CFHR1-3∆ (ref. 8) .
We genotyped CFHR1-3∆ and 20 common SNPs within the CFH and CFHR1-CFHR3 region in 711 individuals with visually impairing advanced AMD of AMD and 1041 controls (see Supplementary Methods) with the Affymetrix 6.0 chip 9 . This genotyping included the rs10801555 SNP, a close proxy for Y402H (r 2 = 0.99 in a subset of 288 genotyped controls), located 1 kb away, and also the rs10737680 SNP, a perfect proxy for the rs1410996 allele (r 2 = 1 in Centre d'Etude du Polymorphisme Humain (CEU) HapMap) located 17.5 kb away in the ninth CFH intron. CFHR1-3∆ frequencies in affected and unaffected individuals were similar to those of Hughes et al. 1 and correlated closely with the rs7542235 SNP (r 2 = 0.98).
First, we tested each of the 21 markers individually ( Fig. 1a and Supplementary Table  1) . We reproduced associations at the CFH Y402H allele (P = 1.5 × 10 −39 at rs10801555) and the CFH rs10737680 allele (P = 1.8 -10 −37 ). We observed more modest evidence of association of CFHR1-3∆ (P = 7.0 × 10 −23 ), with 22% frequency in affected individuals compared to 10% in controls.
Second, because Y402H (rs10801555), rs10737680, and CFHR1-3∆, are in linkage disequilibrium (LD) (D′ ≥ 0.99), we used conditional logistic regression to assess whether they independently conferred risk ( Table 1) . A univariate analysis demonstrated significant association to disease for each marker. When we conditioned on Y402H alone, the CFHR1-3∆ effect was present (odds ratio 0.58, 95% confidence interval 0.46-0.72, P = 2 × 10 −6 ), as previously reported 1 . However, when we conditioned on rs10737680, the statistical strength of the protective effect of CFHR1-3∆ was substantially mitigated (0.72, 0.55-0.95, P = 0.02), though not entirely eliminated. At the same time, conditioning on CFHR1-3∆ did not mitigate the effect of the Y402H and rs10737680 associations (P < 1 × 10 −13 ). On the basis of these results, we concluded that the previously reported associations at CFHR1-3∆ and rs10737680 were not entirely independent.
To better understand the disease association within that locus, we identified common haplotypes of 21 biallelic markers ( Fig.  1b and Supplementary Table 2) . A total of seven haplotypes with frequencies >1% accounted for 95.7% of 3,354 chromosomes. The most frequent H1 haplotype, containing the Y402H risk allele, was present in 59% of chromosomes from affected individuals but only 37% of control chromosomes. For other haplotypes, we calculated the odds ratio of disease association relative to that of H1. As previously observed 6 , the haplotype risk profiles can be most parsimoniously divided into three groups: high risk (H1, odds ratio = 1; reference), intermediate risk (H2 and H3, odds ratio = 0.60, 95% confidence interval (c.i.) 0.50-0.73) and low risk (H4, H5, H6 and H7, odds ratio = 0.32, 95% c.i. 0.27-0.38). The c o r r e s p o n d e n c e haplotypes within each group had effect sizes that were indistinguishable from each other (P = 0.71 for H2 and H3; P = 0.30 for H4, H5, H6 and H7). The three haplotype groups had distinct effects on AMD risk (P = 6.8 × 10 −43 ), with nonoverlapping confidence intervals; breaking groups to assign independent risk to each of the seven haplotypes did not better define risk (P = 0.43). The haplotype analysis demonstrates the relationship between the CFH rs10737680 association and the CFHR1-3∆ association: both markers tag a collection of low-risk haplotypes. The rs10737680 SNP is closely linked to the low-risk haplotypes but misses the rare (1.2%) H4 haplotype, whereas CFHR1-3∆ misses both H4 and H5. Neither tags all of the low-risk haplotypes perfectly, suggesting that there could be one or more not-yet-identified variants that better explain disease risk.
One parsimonious explanation is a single protective functional variant present on low-risk haplotypes H4-H7, in addition to the Y402H risk allele present on H1; such a variant would have very high LD to rs10737680 (r 2 > 0.9). Alternatively, a risk variant on intermediate risk haplotypes H2 and H3 could also explain the data. We searched for such markers by (i) imputing 171 ungenotyped SNPs with 205 HapMap CEU and Toscani in Italia (TSI) samples as a reference and (ii) imputing 72 ungenotyped CFH SNPs with 812 published cases and controls as a reference 7 (Supplementary Methods). No genotyped or imputed SNP fulfilled these criteria. Potentially, dense resequencing of this region to ascertain all common variants within this region could identify a functional mutation that fulfills the above criteria.
An alternative but less parsimonious explanation would be the presence of multiple protective functional mutations on the H4-H7 haplotypes that confer approximately equal effect on risk. For example, CFHR1-3∆ or a CFH variant in LD on H6 and H7 haplotypes and the rs800292 CFH coding variant (I62V) on H4 and H5 haplotypes might each confer equivalent protection from disease, and this would explain the observed data.
We and others have published examples in which common genomic copy number variation might alter disease risk. For example, the IRGM association to Crohn's disease maps to an upstream deletion in the regulatory region, that affects the expression of the gene itself 10 . However, these results suggest the possibility that CFHR1-3∆ may not confer any independent risk of AMD, but may simply be associated with protective CFH haplotypes.
Note: Supplementary information is available on the Nature Genetics website.
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Hughes et al. reply:
The correspondence by Raychaudhuri et al. 1 is in response to our publication in 2006 reporting that a common deletion of CFHR1 and CFHR3 is associated with lower risk of age-related macular degeneration (AMD) 2 .
In both of these studies, many SNPs were genotyped in individuals with AMD and controls, and risk data based on haplotypes were presented. We are pleased to reply and discuss points relating to the interpretation of genetic association data in this complex genomic region that has high, but incomplete, linkage disequilibrium and contains several related genes in which variation may contribute to AMD risk. Our group was, to our knowledge, the first to identify a common deletion of CFHR3 and CFHR1 associated with the most protective haplotype 2 . This was plausibly functional because of the extremely high homology between CFHR1 and the final exons of CFH, though it is not possible to draw conclusions on function from case-control genetic association studies. Since 2005, when the CFH Y402H allele (rs1061170) was shown to be associated strongly with AMD, several groups have reported haplotype risk analysis for the region [2] [3] [4] [5] . The data presented by Raychaudhuri et al. 1 based on 711 individuals with AMD and 1,041 controls (~45% screened) are reasonably comparable to these studies. All have shown notably consistent risk, neutral and protective haplotypes 6 despite often selecting different SNPs for genotyping and using different haplotype block strategies.
In studies in which many SNPs within the CFH gene region have been genotyped, rs2274700, rs1410996, rs10737680, or one of several other markers fully correlated with these SNPs, individually give the most significant P-values for association with AMD. The association data from Raychaudhuri et al. 1 showing a less significant P-value for the deletion (P = 7.0 × 10 −23 ) than for rs10801555 (P = 1.5 × 10 −39 ) or rs10737680 (P = 1.8 × 10 −37 ) is a reflection of allele frequencies rather than effect size, as Table 1 in Raychaudhuri et al. 1 shows that all three confer virtually equal effects (with odds ratios ranging from 0.37 to 0.39). The deletion allele frequencies of 22% in controls and 10% in affected individuals found by Raychaudhuri et al. 1 compare closely with those found (20% and 8%, respectively) by Hughes et al. 2 .
Meta-analysis in Hughes et al. 2 based on 861 individuals with AMD and 441 screened controls reported an odds ratio of 0.43 (95% confidence interval, 0.33-0.54) for the deletion haplotype. Similar meta-analysis using the same combination of Hageman 3 and Hughes et al. 2 data sets for the second protective haplotype tagged by rs800292 (I62V) based on 1,270 individuals with AMD and 612 controls produces an odds ratio of 0.51 (95% confidence interval, 0.42-0.62). Raychaudhuri et al. 1 report, for the equivalent haplotypes (H6-H7 and H4-H5), odds ratios of 0.38 and 0.47, respectively, when presented in the same format.
We reanalyzed the Hughes et al. 2 data set, first using the model presented by Raychaudhuri et al. in Table 1 (ref. 1 ) with Y402H and counts of haplotypes 4 plus 5 (which are equivalent to the minor allele of rs10737680) and, second, using our preferred model based on three potentially functional elements: Y402H, rs800292 and deletion of CFHR3-CFHR1 (for which rs6677604 and others can be used as a proxy), and found the latter (less parsimonious but more functionally based) model to be superior. As the two logistic regression models contained different numbers of parameters and were not nested, their fit to the Hughes et al. 2 data set was best assessed with the Akaike information criterion (AIC), which adjusts the maximized log likelihood to take account of the number of parameters fitted in the model. The AIC value for the model of Raychaudhuri et al. 1 Along with CFH, the previous associations with AMD of variants in C3, CFB and CFI strongly implicate regulation of the alternative complement pathway in the mechanism of susceptibility to AMD. Variation in one or more of these factors may contribute to an individual's risk. The >350-kb region encompassing CFH and five expressed CFH-related genes is more difficult to analyze than many other regions of complex copy number variation. The effect on AMD risk of the rarer deletion of the CFHR1-CFHR4 genes 7 , and other unconfirmed rearrangements and variations that have not yet been genotyped in either the Raychaudhuri et al. 1 or Hughes et al. 2 data sets remain to be elucidated.
Although it may be most parsimonious to attempt to model risk with the fewest functional elements, we argue that this is unnecessarily restrictive. Within the CFH region, AMD risk in the data set of Raychaudhuri et al. 1 can only be predicted with two contributing factors if their rare H4 haplotype is ignored, but full risk information can be extracted from their data by genotyping a minimum of three factors.
Early functional studies support our preferred interpretation of both data sets, with risk based on Y402H, I62V and CFHR1-CFHR3 deletion status. The Y402H polymorphism affects the specificity and affinity of CFH for glycosaminoglycans on cell surfaces, and possibly also for C-reactive protein (CRP), leading to altered retention of CFH and regulation of complement activity on the retinal surface 8, 9 . The I62V polymorphism is a conservative change in CFH; however, there is some evidence that the protective I62 allele may have higher binding affinity for C3b, thus inhibiting proconvertase formation and inactivating fluid and surface-bound
